Mussallem Michael A's Form 4 filing
Edwards Lifesciences Corp (EW) · filed Mar 22, 2022
- Accession no.
- 0001225208-22-004988
- Filed
- Mar 22, 2022
- Trade date
- Mar 22, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.66M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mussallem Michael ACIK 0001204551 | Director, Officer (Chairman & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 22, 2022 | Common Stock | MOption exerciseAcquired | +45,050 | $21.76 | +$980,288 | 124,321.82 | Direct | |
| Mar 22, 2022 | Common Stock | SSaleDisposed | −2,300 | $109.79F2 | −$252,517 | 122,021.82 | Direct | |
| Mar 22, 2022 | Common Stock | SSaleDisposed | −3,000 | $110.86F3 | −$332,580 | 119,021.82 | Direct | |
| Mar 22, 2022 | Common Stock | SSaleDisposed | −4,301 | $112.06F4 | −$481,970.06 | 114,720.82 | Direct | |
| Mar 22, 2022 | Common Stock | GGiftDisposed | −12,500 | $0.00 | $0 | 102,220.82 | Direct | |
| Mar 22, 2022 | Common Stock | SSaleDisposed | −22,949 | $112.87F5 | −$2,590,253.63 | 79,271.82 | Direct | |
| Mar 22, 2022 | Common Stock | GGiftAcquired | +12,500 | $0.00 | $0 | 3,381,517 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 22, 2022 | Common Stock | MOption exerciseDisposed | −45,050 | $0.00 | $0 | 90,100 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $109.38 to $110.35. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $110.44 to $111.42. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $111.49 to $112.47. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $112.50 to $113.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.